Analysis of risk factors for severe acute GVHD
| Factor . | OR . | 95% CI . | P . |
|---|---|---|---|
| RIFNγIntron1-3/3 | 3.92 | 1.24-12.44 | .020 |
| RIFNγIntron1-2+ | 0.33 | 0.11-1.01 | .052 |
| RIL-6−174GG | .636 | 0.18-2.21 | .477 |
| RIL-6−174G+ | 3.46 | 0.42-28.81 | .251 |
| RIL-10−1064i(12-16)+ | 4.61 | 1.20-17.75 | .026 |
| RTNFd3d3 | 3.29 | 1.06-10.15 | .039 |
| R age (per y) | 1.06 | 1.00-1.13 | .068 |
| R age (< 25 y) | 0.18 | 0.39-0.88 | .034 |
| RCMV+ | 1.11 | 0.37-3.35 | .858 |
| R male | 2.78 | 0.72-10.74 | .139 |
| D age (per y) | 1.04 | 0.99-1.10 | .123 |
| D female | 0.68 | 0.22-2.09 | .502 |
| D female into R male | 1.80 | 0.56-5.74 | .321 |
| MTX and/or steroid | 0.55 | 0.14-2.14 | .386 |
| Factor . | OR . | 95% CI . | P . |
|---|---|---|---|
| RIFNγIntron1-3/3 | 3.92 | 1.24-12.44 | .020 |
| RIFNγIntron1-2+ | 0.33 | 0.11-1.01 | .052 |
| RIL-6−174GG | .636 | 0.18-2.21 | .477 |
| RIL-6−174G+ | 3.46 | 0.42-28.81 | .251 |
| RIL-10−1064i(12-16)+ | 4.61 | 1.20-17.75 | .026 |
| RTNFd3d3 | 3.29 | 1.06-10.15 | .039 |
| R age (per y) | 1.06 | 1.00-1.13 | .068 |
| R age (< 25 y) | 0.18 | 0.39-0.88 | .034 |
| RCMV+ | 1.11 | 0.37-3.35 | .858 |
| R male | 2.78 | 0.72-10.74 | .139 |
| D age (per y) | 1.04 | 0.99-1.10 | .123 |
| D female | 0.68 | 0.22-2.09 | .502 |
| D female into R male | 1.80 | 0.56-5.74 | .321 |
| MTX and/or steroid | 0.55 | 0.14-2.14 | .386 |
Risk factors for severe (grades III-IV) aGVHD by logistic regression. Recipient IFNγ, IL-10−1064, and TNFd genotype associate with severe aGVHD.
CI indicates confidence interval; R, recipient; D, donor.